Sign Up to like & get
recommendations!
0
Published in 2020 at "Pediatrics"
DOI: 10.1542/peds.146.1_meetingabstract.592
Abstract: Purpose: In a pivotal phase 3 trial in children (6–12 years) with attention-deficit/hyperactivity disorder (ADHD), evening-dosed HLD200, a delayed-release and extended-release methylphenidate (DR/ER-MPH), significantly improved ADHD symptoms and reduced functional impairment versus placebo (PBO), the…
read more here.
Keywords:
release extended;
release methylphenidate;
delayed release;
morning ... See more keywords